[4]
Boddu, S.H.S.; Menees, A.L.; Ray, A.; Mitra, A.K. A Brief Overview of Ocular Anatomy and Physiology. In: Mitra AK, Ed. Treatise on
Ocular Drug Delivery. Sharjah, UAE: Bentham Science Publishers
2013; pp. 3-19.
[15]
Miller, N.R.; Newman, N.J. Eds Embryology, anatomy, and physiology
of the afferent visual pathway. Miller NR, Newman NJ, Eds.
Walsh & Hoyt’s Clinical Neuro-Ophthalmology Philadelphia: Lippincott
Williams & Wilkins 2005; 1.
[50]
Harikumar, S.L.; Arora, S. Nanotechnological approaches in Ophthalmic delivery systems. Int J Drug Dev & Res, 2011, 3(4), 9-19.
[58]
Tseng, C.L.; Chen, K.H.; Su, W.Y.; Lee, Y.H.; Wu, C.C.; Lin, F.H. Cationic gelatin nanoparticles for drug delivery to the ocular surface: In vitro and In vivo Evaluation. J. Nanomater., 2013, •••, 1-11.
[72]
Moghimipour, E.; Salimi, A.; Yousefvand, T. Preparation and evaluation of celecoxib nanoemulsion for ocular drug delivery. AJP, 2017, 11(3), S543-S550.
[73]
Morsi, N.M.; Mohamed, M.I.; Refai, H.; El Sorogy, H.M. Nanoemulsion as a novel ophthalmic delivery system for acetazolamide. Int. J. Pharm. Pharm. Sci., 2014, 6(11), 227-236.
[99]
Chauhan, S.; Batra, S. Development and in vitro characterization of nanoemulsion embedded thermosensitive in-situ ocular gel of diclofenac sodium for sustained delivery. Int. J. Pharm. Sci. Res., 2018, 9(6), 2301-2314.
[104]
Yunshin, QS Antimicrobial medical device containing silver
nanoparticles. JP2,010,521,697 A (2008).
[105]
Wang, LR; Wang, Y; Wang, SLW; Jingjing, JC; Xingguo, H Seed
crystal nanoparticles tetrandrine ophthalmic formulation and preparation
method. CN1,05,726,484 B (2016).
[106]
Yamamoto, K; Yamamoto, S; Manabe, SH Vitreous stain and staining
methods of the eye, including fluorescent nanoparticles.
JP4,936,508 B2 (2006).
[107]
Jialu, WLR; Ruijuan, LWL; Ze, ZFW Puerarin and scutellarin lipid
nanoparticle ophthalmic preparation and preparation method thereof.
CN1,08,066,315 A (2016).
[108]
Kang, Z. The use of the red cell membrane wrapped ophthalmic
drug. CN1,03,550,223B (2015).
[109]
Campora, G. Nanoparticle ophthalmic composition for the treatment
of ocular disorders or diseases. US20,190,070,242 A1 (2018).
[110]
Chen, H; Enlow, EM; Popov, A Pharmaceutical nanoparticles showing
improved mucosal transport. AU2,013,256,092 B2 (2017).
[111]
Li, CY; Li, YP; Ying, WH; Hangping, C Timolol maleate cubic liquid
crystal nanoparticle eye drops and preparation method thereof.
CN1,06,619,573 A (2016).
[112]
Qiu, Y; Lally, JM Antimicrobial medical devices containing silver
nanoparticles. CA2,530,041 (2005).
[113]
Naash, MI; Cooper, MJ Use of compacted nucleic acid nanoparticles
in non-viral treatments of ocular diseases. WO2,008,137,066 A1 (2008).
[114]
Davis, ME; Davishan, ME; Han, H Nanoparticles stabilized by nitrophenylboronic
acid composition. JP2,019,108,372A (2019).
[115]
Lee, HC Drug delivery implant for treating eye diseases, and preparation
method therefore. WO2,019,160,306A1 (2019).
[116]
Lopes, FP; Jose, E Compositions of jasmonate compounds and
methods of use. US20,180,000,958 A1 (2018).
[117]
Fan, S; Cha, GH; Kang, H; Sung, BK Bland nanoemulsion ophthalmic
composition of cyclosporin-containing. JP5,986,296 B2 (2012).
[118]
Junyoubi, J; Singh, J; Singh, Y; Ryu, Y; Bui, SRY Nanoemulsion
ophthalmic compositions and methods for their preparation containing
cyclosporine. JP6,392,858 B2 (2014).
[119]
Simonnet, JT; Sonneville, O; Legret, S Nanoemulsion, composition
for topical, ophthalmic support, pharmaceutical composition, cosmetic
use of the nanoemulsion cosmetic care process and / or hydration,
and use of the nanoemulsion preparation of a nanoemulsion
process. BR9,906,206 A (1998).
[120]
Sonneville, O; Simonnet, JT Oil-in-water nanoemulsions for cosmetic,
dermatological, pharmaceutical and ophthalmic use contain
amphiphilic lipid and anionic polymer. FR2,809,010 A1 (2000).
[121]
Liang, LC; Li, Z; Cui, Y; Zongxi, HL Nanoemulsion form ophthalmic
composition. CN1,03,282,044 B (2011).
[122]
Quemin, E. Translucent oil-in-water nanoemulsion useful for preparing
cosmetic, dermatological or ophthalmological compositions
comprises three specified surfactants. FR2,819,427 A1 (2001).
[123]
Legret, S; Simonnet, JT; Sonneville, O Nanoemulsion based on
mixed esters of a fatty acid or alcohol, of a carboxylic acid and
glyceryl, and uses thereof in the cosmetical, dermatological and/or
ophtalmological fields. EP1,010,414 B1 (1998).
[124]
Simonnet, JT; Sonneville, O; Legret, S Nanoemulsion based on
alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of
glucose and its uses in the cosmetics, dermatological, opthalmological
and/or pharmaceutical fields. US6,461,625 B1 (1999).
[125]
Arumugham, R; Upadhyay, AK Ophthalmic compositions and methods
of use. US20,190,008,920 A1 (2018).
[126]
Sasaki, K; Okumura, T; Hattori, M Ophthalmic composition
including high sorbability vitamin a-including nanoemulsion particle
and method for producing the same. JP2,013,253,063 A (2012).
[127]
Carrimilan, F; Schmidt, BR; Chieri, E Ophthalmic oil-in-water emulsion
containing prostaglandin. JP5,452,472 B2 (2007).
[128]
Bokyung, FY; Ho, CG Ophthalmic nano-emulsion composition
containing cyclosporin for the treatment of dry-eye-syndrome.
KR1,01,008,189 B1 (2010).
[129]
GmbH. Micro- or nano-emulsion for ophthalmic use.
DE2,02,014,010,412 U1 (2014).
[130]
Lee, JHY; Lee, JS; Lee, GY; Choi, S-II Opthalmic composition in
form of nanoemulsion. KR1,01,151,235 B1 (2011).
[131]
Mitra, AK; Velagaleti, PR; Grau, UM Topical drug delivery systems
for ophthalmic use. WO20,101,441,94A1 (2010).
[132]
Maitra, A; Gupta, AK; Majumdar, D; Madan, S Sustained release and
long residing ophthalmic formulation and the process of preparing
the same. US6,579,519 B2 (2001).
[133]
Chauhan, A; Gulsen, D Ophthalmic drug delivery system.
US8,273,366 B2 (2004).
